Feasibility of CGM Use in Hospitalized Youth

February 27, 2026 updated by: University of Colorado, Denver

Feasibility of Continuous Glucose Monitor Use In Hospitalized Youth

This study is assessing the feasibility of a continuous glucose monitor during hospital admissions in youth and young adults with hyperglycemia due to diabetes or other underlying conditions that requires frequent glucose monitoring, through patient/family and nursing staff feedback on their perspectives and usability of the system in the hospital will be assessed through surveys. In addition, retrospective glycemic comparisons between CGM data and POC will be conducted.

Study Overview

Status

Enrolling by invitation

Conditions

Detailed Description

Youth and young adult patients admitted to the hospital for any reason, but require glucose monitoring during the hospitalization will be enrolled in this study. Participant diagnosis can include type 1 diabetes, type 2 diabetes, medication-induced diabetes, cystic fibrosis-related diabetes, or other causes of hyperglycemia that it has been determined by the hospital team requires frequent glucose monitoring, with or without insulin management.

Enrolled participants will wear a blinded continuous glucose monitor for up to 28 days (2 sensors) or until the end of their hospitalization. In addition, enrolled participants will complete a survey to assess their perspectives on the CGM wear experience and interest in future CGM use during hospitalizations. Nursing staff of the enrolled participant will also be invited to complete a survey regarding their perspectives of CGM use in the hospital setting.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Francisco, California, United States, 94158
        • University of California San Francisco
      • Stanford, California, United States, 94305
        • Stanford University
    • Colorado
      • Aurora, Colorado, United States, 80045
        • University Of Colorado, Barbara Davis Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Youth and young adult participants will be admitted to the hospital and have hyperglycemia resulting in an endocrine consult and requiring frequent glucose monitoring.

Nursing staff providing medical care for the youth and young adult participant will be invited to complete a survey on usability of the CGM in the hospital setting.

Description

Inclusion Criteria:

  1. Participants will be 2 to less than 26 years of age at the time of enrollment.
  2. Participants will have a diagnosis of type 1 diabetes, type 2 diabetes, diabetes/hyperglycemia due to an underlying condition (such as in cystic fibrosis, monogenic diabetes), or medication induced diabetes/hyperglycemia (such as steroid-induced hyperglycemia or PEG-asparaginase induced hyperglycemia) and would benefit clinically from close glucose monitoring during hospitalization due to fluctuations in blood glucose values.
  3. Participant is expected to be in the hospital for longer than 12 hours after study enrollment with a goal of 36 hours or more as determined by study investigator or trained staff.
  4. Participant is willing to wear the continuous glucose monitor for the duration of the hospital admission or the lifespan of a continuous glucose monitor (7-14 days).

Exclusion Criteria:

  1. Has had a history of a significant skin reaction to the adhesives of a continuous glucose monitor in the past or concerns that one may occur due to underlying skin conditions (ie severe eczema, uncontrolled psoriasis, etc).
  2. Planned MRI or surgery during the study device use (can be enrolled pre or post procedure if sufficient time for sensor wear as determined by investigator [i.e. 24-48 before planned procedure]).
  3. Admission to inpatient psychiatry.
  4. Pregnancy.
  5. Currently using hydroxyurea.
  6. A condition that the investigator determines would prevent the patient from participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
You and young adult patients with hyperglycemia
Any youth and young adult patient admitted to the hospital and requiring an endocrine consult for frequent glucose monitoring and hyperglycemia management
Youth and young adult participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
Nursing staff
Nursing staff providing medical care for youth and young adult patients enrolled in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Retrospective glycemic CGM and point of care comparison
Time Frame: Duration of study, approximately 1 year from study start
Glycemic data related to time in range, time hypoglycemic, time hyperglycemic and the time of first onset of hypoglycemia and hyperglycemia will be obtained by both CGM and point of care glucose values.
Duration of study, approximately 1 year from study start

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nursing staff perspectives of CGM use in the hospital
Time Frame: Duration of study, approximately to 1 year from study start
Surveys will be provided to the nursing staff associated with an enrolled patient participant to obtain qualitative perspectives on the usability of CGMs in the hospital setting
Duration of study, approximately to 1 year from study start
Patient/Family perspectives of CGM use in the hospital
Time Frame: Duration of study, approximately 1 year from study start
Surveys will be completed by patients/family to evaluate their experience with sensor wear in the hospital, sensor insertion, and goals for glycemic monitoring while in the hospital.
Duration of study, approximately 1 year from study start
Feasibility of CGM use through assessment of discontinuation and data loss
Time Frame: Duration of study, approximately 1 year from study start
Identify the frequency and causes of sensor discontinuation as well as information on sensor data loss.
Duration of study, approximately 1 year from study start
Health economics data
Time Frame: Duration of study, approximately 1 year from study start
Pilot analysis of health economics data from costs related to glycemic monitoring during the hospitalization.
Duration of study, approximately 1 year from study start

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2025

Primary Completion (Estimated)

February 14, 2027

Study Completion (Estimated)

February 14, 2027

Study Registration Dates

First Submitted

November 9, 2023

First Submitted That Met QC Criteria

November 15, 2023

First Posted (Actual)

November 22, 2023

Study Record Updates

Last Update Posted (Actual)

March 3, 2026

Last Update Submitted That Met QC Criteria

February 27, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperglycemia

Clinical Trials on Freestyle Libre 3 Continuous Glucose Monitor

Subscribe